Literature DB >> 11129017

Time to first relapse as an outcome and a predictor of survival in patients with squamous cell carcinoma of the head and neck.

S F Hall1, P A Groome, D Rothwell.   

Abstract

OBJECTIVE: To identify patterns and predictors of relapse and to determine whether the time to relapse influences survival. STUDY
DESIGN: Multivariate anal. ysis of prospective database.
METHODS: We present findings in 446 consecutive prospective patients from a regional cancer center with invasive squamous cell carcinoma who were treated for cure and were declared disease free. Time to relapse, site of relapse, and survival are reported by stage and site using bivariate and multivariate analysis.
RESULTS: Thirty-six percent of patients relapsed. The median time to relapse was 8.3 months, and 95% of relapses occurred within 3 years. T stage in the TNM staging system was associated with relapse, and N stage was not. In patients who relapsed before the median time to relapse, prognosis was worse than in those who relapsed after that time.

Entities:  

Mesh:

Year:  2000        PMID: 11129017     DOI: 10.1097/00005537-200012000-00012

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  Characterizing head and neck cancer survivors' discontinuation of survivorship care.

Authors:  Aaron T Seaman; Kristen L Seligman; Khanh K Nguyen; Zaid Al-Qurayshi; Nicholas D Kendell; Nitin A Pagedar
Journal:  Cancer       Date:  2021-08-30       Impact factor: 6.860

2.  Variation in routine follow-up care after curative treatment for head-and-neck cancer: a population-based study in Ontario.

Authors:  K E Brennan; S F Hall; T E Owen; R J Griffiths; Y Peng
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

3.  Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK.

Authors:  Kun Kim; Mayur M Amonkar; Daniel Högberg; Frida Kasteng
Journal:  Head Neck Oncol       Date:  2011-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.